ATE324116T1 - Ein antigen und ein adjuvans-peptid enthaltende impfstoffzusammensetzung - Google Patents
Ein antigen und ein adjuvans-peptid enthaltende impfstoffzusammensetzungInfo
- Publication number
- ATE324116T1 ATE324116T1 AT01980496T AT01980496T ATE324116T1 AT E324116 T1 ATE324116 T1 AT E324116T1 AT 01980496 T AT01980496 T AT 01980496T AT 01980496 T AT01980496 T AT 01980496T AT E324116 T1 ATE324116 T1 AT E324116T1
- Authority
- AT
- Austria
- Prior art keywords
- peptide
- antigen
- amino acid
- acid residue
- composition containing
- Prior art date
Links
- 239000000427 antigen Substances 0.000 title abstract 3
- 102000036639 antigens Human genes 0.000 title abstract 3
- 108091007433 antigens Proteins 0.000 title abstract 3
- 229960005486 vaccine Drugs 0.000 title abstract 2
- DLQPMEMYCIGJIM-UHFFFAOYSA-N Adjuvant peptide Natural products CC(NC(=O)CCOC1C(O)C(CO)OC(O)C1NC(=O)C)C(=O)NC(CCC(=O)O)C(=O)N DLQPMEMYCIGJIM-UHFFFAOYSA-N 0.000 title 1
- BSOQXXWZTUDTEL-QAQREVAFSA-N muramyl dipeptide Chemical compound OC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)OC(O)[C@@H]1NC(C)=O BSOQXXWZTUDTEL-QAQREVAFSA-N 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 6
- 125000000539 amino acid group Chemical group 0.000 abstract 3
- 125000001433 C-terminal amino-acid group Chemical group 0.000 abstract 1
- 230000033289 adaptive immune response Effects 0.000 abstract 1
- 150000001408 amides Chemical class 0.000 abstract 1
- 230000002708 enhancing effect Effects 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 150000007970 thio esters Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pulmonology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- AIDS & HIV (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AT0178900A AT410635B (de) | 2000-10-18 | 2000-10-18 | Vakzin-zusammensetzung |
EP01980496A EP1326634B1 (de) | 2000-10-18 | 2001-10-18 | Ein antigen und ein adjuvans-peptid enthaltende impfstoffzusammensetzung |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE324116T1 true ATE324116T1 (de) | 2006-05-15 |
Family
ID=3688953
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT0178900A AT410635B (de) | 2000-10-18 | 2000-10-18 | Vakzin-zusammensetzung |
AT01980496T ATE324116T1 (de) | 2000-10-18 | 2001-10-18 | Ein antigen und ein adjuvans-peptid enthaltende impfstoffzusammensetzung |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT0178900A AT410635B (de) | 2000-10-18 | 2000-10-18 | Vakzin-zusammensetzung |
Country Status (27)
Country | Link |
---|---|
US (3) | US8361476B2 (de) |
EP (1) | EP1326634B1 (de) |
JP (2) | JP4227407B2 (de) |
KR (1) | KR100598302B1 (de) |
CN (1) | CN1248736C (de) |
AT (2) | AT410635B (de) |
AU (2) | AU2002212326B2 (de) |
BR (1) | BRPI0114994B8 (de) |
CA (1) | CA2426490C (de) |
CZ (1) | CZ303303B6 (de) |
DE (1) | DE60119145T2 (de) |
DK (1) | DK1326634T3 (de) |
ES (1) | ES2263668T3 (de) |
HK (1) | HK1055899A1 (de) |
HU (1) | HU228382B1 (de) |
IL (2) | IL154605A0 (de) |
IS (1) | IS2608B (de) |
MX (1) | MXPA03002828A (de) |
NO (1) | NO330274B1 (de) |
NZ (1) | NZ524532A (de) |
PL (1) | PL209016B1 (de) |
PT (1) | PT1326634E (de) |
RU (2) | RU2328305C2 (de) |
SI (1) | SI1326634T1 (de) |
SK (1) | SK287618B6 (de) |
WO (1) | WO2002032451A1 (de) |
ZA (1) | ZA200301465B (de) |
Families Citing this family (80)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AT410635B (de) * | 2000-10-18 | 2003-06-25 | Cistem Biotechnologies Gmbh | Vakzin-zusammensetzung |
JP2004519452A (ja) * | 2001-01-05 | 2004-07-02 | インターツェル・アクチェンゲゼルシャフト | ポリカチオン性化合物の用途 |
US7244438B2 (en) | 2001-01-05 | 2007-07-17 | Intercell Ag | Uses for polycationic compounds |
AT410798B (de) | 2001-01-26 | 2003-07-25 | Cistem Biotechnologies Gmbh | Verfahren zur identifizierung, isolierung und herstellung von antigenen gegen ein spezifisches pathogen |
EP1279404A1 (de) | 2001-07-26 | 2003-01-29 | Istituto Superiore di Sanità | Verwendung von HIV-1 Fragmenten oder Derivaten zur Bestimmung oder Aktivierung von Antigen-präsentierenden Zellen, oder zur Abgabe von Cargo-Molekülen für Impfung oder für Behandlung von anderen Erkrankungen |
MX339524B (es) | 2001-10-11 | 2016-05-30 | Wyeth Corp | Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica. |
JP2005533855A (ja) | 2002-07-24 | 2005-11-10 | インターツェル・アクチェンゲゼルシャフト | 病原性ウイルスからの別のリーディングフレームによりコードされる抗原 |
US7785608B2 (en) | 2002-08-30 | 2010-08-31 | Wyeth Holdings Corporation | Immunogenic compositions for the prevention and treatment of meningococcal disease |
JP2006504687A (ja) | 2002-09-13 | 2006-02-09 | インターツェル・アクチェンゲゼルシャフト | C型肝炎ウイルスペプチドの単離方法 |
WO2004035618A2 (en) | 2002-10-15 | 2004-04-29 | Intercell Ag | Nucleic acids coding for adhesion factor of group b streptococcus, adhesion factors of group b streptococcus and further uses thereof |
DE602004022923D1 (de) | 2003-03-04 | 2009-10-15 | Intercell Ag | Streptococcus pyogenes antigene |
WO2004084937A1 (en) * | 2003-03-24 | 2004-10-07 | Intercell Ag | Use of alum and a th1 immune response inducing adjuvant for enhancing immune responses |
ES2562456T3 (es) * | 2003-03-24 | 2016-03-04 | Valneva Austria Gmbh | Uso de un adyuvante que induce una respuesta inmune Th1 para mejorar las respuestas inmunes |
JP2007523609A (ja) | 2003-03-31 | 2007-08-23 | インターツェル・アクチェンゲゼルシャフト | 表皮ブドウ球菌抗原 |
CA2522238A1 (en) | 2003-04-15 | 2004-10-28 | Intercell Ag | S. pneumoniae antigens |
US8076059B2 (en) | 2003-04-16 | 2011-12-13 | Duke University | Adjuvant capable of specifically activating the adaptive immune response |
JP2007535894A (ja) | 2003-05-07 | 2007-12-13 | インターツェル・アクチェンゲゼルシャフト | ストレプトコッカス・アガラクティエ抗原i+ii |
EP2327720A1 (de) | 2003-05-30 | 2011-06-01 | Intercell AG | Enterokokken-Antigene |
CN1822856B (zh) * | 2003-07-11 | 2010-04-28 | 英特塞尔股份公司 | Hcv疫苗 |
ES2297688T3 (es) | 2004-03-12 | 2008-05-01 | Intercell Ag | Procedimiento para solubizar mezclas de peptidos. |
ES2344739T3 (es) | 2004-09-24 | 2010-09-06 | Intercell Ag | Proteina capsidial vp1 modificada del parvovirus b19. |
EP2471550A1 (de) | 2005-10-07 | 2012-07-04 | Health Protection Agency | Proteine mit verbesserter Löslichkeit und Verfahren zu ihrer Herstellung und Verwendung |
TW200806315A (en) | 2006-04-26 | 2008-02-01 | Wyeth Corp | Novel formulations which stabilize and inhibit precipitation of immunogenic compositions |
WO2008000261A2 (en) | 2006-06-28 | 2008-01-03 | Statens Serum Institut | Expanding the t cell repertoire to include subdominant epitopes by vaccination with antigens delivered as protein fragments or peptide cocktails |
JP2009542196A (ja) | 2006-07-07 | 2009-12-03 | インターセル アーゲー | 小型の化膿連鎖球菌抗原およびそれらの使用 |
AU2007295927A1 (en) | 2006-09-15 | 2008-03-20 | Intercell Ag | Borrelia antigens |
EP1923069A1 (de) | 2006-11-20 | 2008-05-21 | Intercell AG | Schutzpeptide gegen S. pneumoniae und diesbezügliche Zusammensetzungen, Verfahren und Verwendungen |
AR064642A1 (es) | 2006-12-22 | 2009-04-15 | Wyeth Corp | Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi |
CA2675379A1 (en) | 2007-01-12 | 2008-07-17 | Intercell Ag | Protective proteins of s. agalactiae, combinations thereof and methods of using the same |
US8236326B2 (en) | 2007-05-02 | 2012-08-07 | Intercell Ag | Klebsiella antigens |
US20100203083A1 (en) | 2007-05-31 | 2010-08-12 | Medigene Ag | Mutated structural protein of a parvovirus |
EP2012122A1 (de) | 2007-07-06 | 2009-01-07 | Medigene AG | Strukturproteine von mutierten Parvoviren als Impfstoffe |
EP2167530A2 (de) | 2007-06-18 | 2010-03-31 | Intercell AG | Chlamydia-antigene |
CA2718473A1 (en) | 2008-03-17 | 2009-09-24 | Intercell Ag | Peptides protective against s. pneumoniae and compositions, methods and uses relating thereto |
EP2281574B1 (de) | 2008-04-02 | 2014-07-09 | The University of Tokushima | Antigen-und-arznei-vehikel mit einem synthetischen peptid und dieses verwendender mukosaler impfstoff |
KR20110031343A (ko) | 2008-06-20 | 2011-03-25 | 와이어쓰 엘엘씨 | 베타-용혈성 스트렙토코커스 균주로부터 유래된 orf1358을 사용하는 조성물 및 방법 |
US20100015171A1 (en) * | 2008-07-15 | 2010-01-21 | Statens Serum Institute | Vaccines comprising tb 10.4 |
US20130243779A1 (en) | 2009-02-05 | 2013-09-19 | Intercell Ag | Peptides protective against e. faecalis, methods and uses relating thereto |
US8617574B2 (en) | 2009-02-13 | 2013-12-31 | Valneva Austria Gmbh | Nontypable Haemophilus influenzae antigens |
PE20110023A1 (es) | 2009-06-22 | 2011-01-31 | Wyeth Llc | Composiciones inmunogenicas de antigenos de staphylococcus aureus |
EP3461496B1 (de) | 2009-06-22 | 2023-08-23 | Wyeth LLC | Zusammensetzungen und verfahren zur herstellung von staphylococcus aureus serotyp-5 und 8-kapselpolysaccharid-konjugat-immunogenzusammensetzungen |
NZ598459A (en) | 2009-08-27 | 2014-03-28 | Novartis Ag | Adjuvant comprising aluminium, oligonucleotide and polycation |
EP2319871A1 (de) | 2009-11-05 | 2011-05-11 | Sanofi-aventis | Polypeptide zum Binden an den Rezeptor für weiterentwickelte Glykierungsendprodukte sowie Zusammensetzungen und Verfahren, die diese Polypeptide beinhalten |
PE20121689A1 (es) | 2009-10-09 | 2012-12-14 | Sanofi Sa | Polipeptidos para union al receptor para productos finales de glicosilacion avanzada asi como composiciones y metodos que implican a los mismos |
EP2308896A1 (de) | 2009-10-09 | 2011-04-13 | Sanofi-aventis | Polypeptides zum Binden an den Rezeptor für weiterentwickelte Glykierungsendprodukte sowie Zusammensetzungen und Verfahren, die diese Polypeptide beinhalten |
US8765148B2 (en) | 2010-02-19 | 2014-07-01 | Valneva Austria Gmbh | 1C31 nanoparticles |
JP2013522287A (ja) | 2010-03-18 | 2013-06-13 | ノバルティス アーゲー | 血清群b髄膜炎菌のためのアジュバント添加ワクチン |
KR101609032B1 (ko) | 2010-06-04 | 2016-04-04 | 와이어쓰 엘엘씨 | 스트렙토코커스 뉴모니아 백신 제제 |
RU2580620C2 (ru) | 2010-08-23 | 2016-04-10 | ВАЙЕТ ЭлЭлСи | СТАБИЛЬНЫЕ КОМПОЗИЦИИ АНТИГЕНОВ Neisseria meningitidis rLP2086 |
BR112014004896B1 (pt) | 2010-09-03 | 2023-02-14 | Valneva Usa, Inc. | Polipepttdeo isolado de proteínas de toxina a e toxina b de c. difficile e usos do mesmo |
WO2012031760A1 (en) | 2010-09-08 | 2012-03-15 | Medigene Ag | Parvovirus mutated structural proteins comprising cross - protective b - cell epitopes of a hpv l2 protein as well as products and methods relating thereto |
PE20140173A1 (es) | 2010-09-10 | 2014-02-20 | Wyeth Llc | Variantes no lipidadas de antigenos orf2086 de neisseria meningitidis |
KR20130114210A (ko) | 2010-12-22 | 2013-10-16 | 와이어쓰 엘엘씨 | 스타필로코커스 아우레우스 항원의 안정한 면역원성 조성물 |
BRPI1100857A2 (pt) * | 2011-03-18 | 2013-05-21 | Alexandre Eduardo Nowill | agente imunomodulador e suas combinaÇÕes, seu uso e mÉtodo imunoterÁpico para a recontextualizaÇço, reprogramaÇço e reconduÇço do sistema imune em tempo real |
ITMI20111182A1 (it) | 2011-06-28 | 2012-12-29 | Canio Buonavoglia | Vaccino per coronavirus canino |
SA115360586B1 (ar) | 2012-03-09 | 2017-04-12 | فايزر انك | تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها |
MY198910A (en) | 2012-03-09 | 2023-10-02 | Pfizer | Neisseria meningitidis compositions and methods thereof |
EP2847322B1 (de) | 2012-05-08 | 2019-06-26 | Western University Of Health Sciences | Standardisierte ex-vivo-plattformen zur antigenspezifischen expansion der cd4+-t-zell-populationen |
WO2014070709A1 (en) * | 2012-10-29 | 2014-05-08 | The Board Of Trustees Of The University Of Arkansas | Novel mucosal adjuvants and delivery systems |
PL3363806T3 (pl) | 2012-12-20 | 2022-12-19 | Pfizer Inc. | Sposób glikokoniugacji |
EP2964665B1 (de) | 2013-03-08 | 2018-08-01 | Pfizer Inc | Immunogene fusionspolypeptide |
US20140271723A1 (en) * | 2013-03-15 | 2014-09-18 | Saint Louis University | Adjuvant compositions and methods of using thereof |
MX369534B (es) | 2013-09-08 | 2019-11-11 | Pfizer | Composiciones de neisseria meningitidis y sus metodos. |
WO2016130569A1 (en) | 2015-02-09 | 2016-08-18 | Mj Biologics, Inc. | A composition comprising pedv antigens and methods for making and using the composition |
CN107249626A (zh) | 2015-02-19 | 2017-10-13 | 辉瑞大药厂 | 脑膜炎奈瑟球菌组合物及其方法 |
TWI718144B (zh) | 2015-05-04 | 2021-02-11 | 美商輝瑞股份有限公司 | B型鏈球菌多醣-蛋白質軛合物、製造軛合物之方法、含軛合物之免疫原性組成物、及其用途 |
CN107441501B (zh) * | 2016-07-01 | 2020-11-10 | 四川大学 | 抗菌肽修饰的载药脂质体及其制备方法和用途 |
US10751402B2 (en) | 2016-11-09 | 2020-08-25 | Pfizer Inc. | Immunogenic compositions and uses thereof |
SG11201906519RA (en) | 2017-01-31 | 2019-08-27 | Pfizer | Neisseria meningitidis compositions and methods thereof |
CN107266585B (zh) * | 2017-07-13 | 2019-08-06 | 陕西科技大学 | 一种mlh融合抗菌肽及其制备方法和应用 |
EP3527223A1 (de) | 2018-02-16 | 2019-08-21 | 2A Pharma AB | Mutiertes parvovirus-strukturprotein |
JP2021513840A (ja) | 2018-02-16 | 2021-06-03 | 2エー ファーマ アーベー | 自己免疫疾患の処置のためのパルボウイルス構造タンパク質 |
CN109745556A (zh) * | 2019-03-01 | 2019-05-14 | 龙阔(苏州)生物工程有限公司 | 一种疫苗佐剂及其应用及猪繁殖与呼吸综合征疫苗 |
AU2020277661A1 (en) | 2019-05-20 | 2021-10-21 | Valneva Se | A subunit vaccine for treatment or prevention of a respiratory tract infection |
US20230137756A1 (en) * | 2020-03-30 | 2023-05-04 | The Wistar Institute Of Anatomy And Biology | Synthetic Soluble Receptor Mimics and Methods of Use for Treatment of COVID-19 |
WO2021211279A1 (en) | 2020-04-17 | 2021-10-21 | Regents Of The University Of Minnesota | SARS-CoV-2 SPIKE RECEPTOR BINDING DOMAIN AND COMPOSITIONS AND METHODS THEREOF |
EP4203995A1 (de) | 2020-08-26 | 2023-07-05 | Pfizer Inc. | Gruppe-b-streptococcus-polysaccharid-protein-konjugate, verfahren zur herstellung von konjugaten, immunogene zusammensetzungen mit konjugaten und verwendungen davon |
JP2024522385A (ja) | 2021-04-09 | 2024-06-19 | ヴァルネヴァ エスイー | ヒトメタニューモウイルスワクチン |
WO2023083964A1 (en) | 2021-11-11 | 2023-05-19 | 2A Pharma Ab | Parvovirus structural protein against beta- and gamma-hpv |
WO2024069420A2 (en) | 2022-09-29 | 2024-04-04 | Pfizer Inc. | Immunogenic compositions comprising an rsv f protein trimer |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH09502086A (ja) * | 1993-08-06 | 1997-03-04 | サイテル コーポレイション | 完全mage1遺伝子のクローニング及び特性決定 |
JP3442824B2 (ja) * | 1993-08-30 | 2003-09-02 | 理化学研究所 | 抗菌性ペプチド類 |
JP3547504B2 (ja) * | 1994-11-01 | 2004-07-28 | 独立行政法人理化学研究所 | 新規なポリペプチド及びその用途 |
US6261568B1 (en) * | 1997-06-11 | 2001-07-17 | Institut Pasteur | Attenuated recombinant mycobacteria useful as immunogens or as vaccine components |
EP1009386B1 (de) * | 1997-08-29 | 2005-08-31 | Corixa Corporation | Schnellfreisetzende enkapsulierte bioaktive wirkstoffe zur induzierung einer immunantwort und verwendung derselben |
CU22700A1 (es) * | 1997-09-29 | 2001-07-31 | Ct Ingenieria Genetica Biotech | Formulación farmacéutica anti-viral que contiene un péptido de la proteína factor anti-lps de limulus y su uso |
US20020072495A1 (en) * | 2000-09-21 | 2002-06-13 | Oleg Chertov | LL-37 is an immunostimulant |
AT410635B (de) | 2000-10-18 | 2003-06-25 | Cistem Biotechnologies Gmbh | Vakzin-zusammensetzung |
ES2562456T3 (es) * | 2003-03-24 | 2016-03-04 | Valneva Austria Gmbh | Uso de un adyuvante que induce una respuesta inmune Th1 para mejorar las respuestas inmunes |
WO2004084937A1 (en) * | 2003-03-24 | 2004-10-07 | Intercell Ag | Use of alum and a th1 immune response inducing adjuvant for enhancing immune responses |
CN1822856B (zh) * | 2003-07-11 | 2010-04-28 | 英特塞尔股份公司 | Hcv疫苗 |
-
2000
- 2000-10-18 AT AT0178900A patent/AT410635B/de not_active IP Right Cessation
-
2001
- 2001-10-18 AU AU2002212326A patent/AU2002212326B2/en not_active Expired
- 2001-10-18 WO PCT/EP2001/012041 patent/WO2002032451A1/en active IP Right Grant
- 2001-10-18 AU AU1232602A patent/AU1232602A/xx active Pending
- 2001-10-18 KR KR1020037004977A patent/KR100598302B1/ko active IP Right Grant
- 2001-10-18 CN CNB018171168A patent/CN1248736C/zh not_active Expired - Lifetime
- 2001-10-18 BR BRPI0114994-6 patent/BRPI0114994B8/pt not_active IP Right Cessation
- 2001-10-18 US US10/399,442 patent/US8361476B2/en active Active
- 2001-10-18 SK SK575-2003A patent/SK287618B6/sk not_active IP Right Cessation
- 2001-10-18 CA CA2426490A patent/CA2426490C/en not_active Expired - Lifetime
- 2001-10-18 NZ NZ524532A patent/NZ524532A/en not_active IP Right Cessation
- 2001-10-18 SI SI200130564T patent/SI1326634T1/sl unknown
- 2001-10-18 RU RU2003114434/15A patent/RU2328305C2/ru active
- 2001-10-18 AT AT01980496T patent/ATE324116T1/de not_active IP Right Cessation
- 2001-10-18 CZ CZ20031299A patent/CZ303303B6/cs not_active IP Right Cessation
- 2001-10-18 DE DE60119145T patent/DE60119145T2/de not_active Expired - Lifetime
- 2001-10-18 PT PT01980496T patent/PT1326634E/pt unknown
- 2001-10-18 PL PL362966A patent/PL209016B1/pl unknown
- 2001-10-18 HU HU0302117A patent/HU228382B1/hu unknown
- 2001-10-18 DK DK01980496T patent/DK1326634T3/da active
- 2001-10-18 JP JP2002535688A patent/JP4227407B2/ja not_active Expired - Lifetime
- 2001-10-18 IL IL15460501A patent/IL154605A0/xx unknown
- 2001-10-18 EP EP01980496A patent/EP1326634B1/de not_active Expired - Lifetime
- 2001-10-18 MX MXPA03002828A patent/MXPA03002828A/es active IP Right Grant
- 2001-10-18 ES ES01980496T patent/ES2263668T3/es not_active Expired - Lifetime
-
2003
- 2003-02-20 IS IS6722A patent/IS2608B/is unknown
- 2003-02-24 ZA ZA200301465A patent/ZA200301465B/en unknown
- 2003-02-24 IL IL154605A patent/IL154605A/en unknown
- 2003-04-08 NO NO20031595A patent/NO330274B1/no not_active IP Right Cessation
- 2003-11-12 HK HK03108189A patent/HK1055899A1/xx not_active IP Right Cessation
-
2007
- 2007-12-13 RU RU2007146372/15A patent/RU2007146372A/ru not_active Application Discontinuation
-
2008
- 2008-05-21 US US12/124,785 patent/US8900564B2/en active Active
- 2008-05-22 JP JP2008134215A patent/JP2008222721A/ja not_active Withdrawn
-
2013
- 2013-01-16 US US13/742,500 patent/US20130216583A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE324116T1 (de) | Ein antigen und ein adjuvans-peptid enthaltende impfstoffzusammensetzung | |
PL324531A1 (en) | Derivatives of cyclosporin effective against hiv virus | |
ATE429448T1 (de) | Peptidzusammensetzung als immunogen zur allergiebehandlung. | |
ATE557041T1 (de) | Peptid-vakzinen gegen streptokokken der gruppe a | |
IL144989A0 (en) | Method for acylating peptides and novel acylating agents | |
ATE442378T1 (de) | Substituierte wt1-peptide | |
DE60039050D1 (de) | Antigene meningokokken peptide | |
DE60127113D1 (de) | Gd3 mimetische peptide | |
ES2176334T3 (es) | El uso de gabapentin en el tratamiento de la ansiedad y el panico. | |
MXPA02012664A (es) | Peptidos para la preparacion de vacunas contra bordetella pertussis y bordetella parapertussis. | |
EA200100314A1 (ru) | Пептидные фрагменты холерного экзотоксина в или энтеротоксина в в качестве адъювантов вакцины | |
NZ508812A (en) | Peptides for the prevention or treatment of HIV | |
WO1994004565A3 (en) | Ipnv vaccine | |
WO2001074847A3 (en) | T-cell epitope of mage-12 and related nucleic acids, vectors, cells, compositions and methods of inducing an immune response to cancer | |
DE60124299D1 (de) | Peptide aus dem b-glycoprotein des menschlichen herpesvirus-7, besonders anwendbar bei serologischen elisa-nachweisen | |
EP0290246A3 (de) | Impfstoff zur Erzeugung einer gegen Tollwutvirus schützenden immunogenen T-Zellen-Respons | |
ECSP003720A (es) | Peptidos modificados y peptidomimeticos para el uso en inmunoterapia |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
UEP | Publication of translation of european patent specification |
Ref document number: 1326634 Country of ref document: EP |
|
REN | Ceased due to non-payment of the annual fee |